Approximately 1 in 5 individuals in the United States alone will experience depression during their lifetime. Current guidelines suggest that monotherapy may be used as initial therapy for major depressive disorder, but what evidence exists suggesting that starting dual anti-depressant therapy may have better outcomes? Join your host, Geoff Wall as he discusses a recent meta-analysis regarding dual therapy in depression.
For initial therapy or patients who are non-respondent to previous treatment, dual anti-depressant therapy may have a small, but significant impact on treatment outcomes, specifically treatment efficacy.
00:00 – Introductions
01:19 – Dual Therapy in Depression
11:57 – Which Anti-Depressant Combination?
15:27 – The GameChanger
18:37 – Closing Remarks
Geoff Wall, PharmD., BCPS, FCCP, CGP
Professor of Pharmacy Practice, Drake University
Internal Medicine/Critical Care, UnityPoint Health
References and resources:
Redeem your CPE or CME credit here!
Need a membership?
Continuing Education Information:
Dr. Wall is a member of the Janssen Speaker's Bureau.
0.05 CEU | 0.5 Hrs
ACPE UAN: 0107-0000-22-143-H01-P
Initial release date: 04/4/22
Expiration date: 04/4/2023
For more information https://www.ceimpact.com/podcast